EBElvan Bakar

Elvan Bakar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elvan Bakar has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Glycan and glycoprotein signatures in tumor-induced liver alterations in a murine breast cancer model

    by Nebiye Pelin Turker, Elvan Bakar

    Liver-associated alterations are increasingly recognized as critical contributors to breast cancer progression and systemic disease burden, yet the molecular mechanisms underlying these changes remain poorly understood. In particular, aberrant protein glycosylation has emerged as a key regulator of cancer-associated tissue remodeling and inter-organ communication. In this study, we investigated whether glycosylation-related gene expression and glycoprotein signatures in liver tissue could serve as biomarkers of breast cancer-associated hepatic alterations. We developed a medium-throughput quantitative real-time reverse transcriptase-PCR array targeting genes encoding glycosyltransferases and glycosylhydrolases involved in glycan synthesis, modification, and catabolism. This approach enabled a systematic analysis of over 134 glycosylation-related genes and facilitated direct integration of transcriptomic data with glycan structural profiles in the liver tissue of breast tumor-bearing mice. Our analysis revealed significant upregulation of Galntl2, GNE, and Manea, accompanied by increased sialic acid levels in both liver and circulating blood. Receiver operating characteristic (ROC) analysis demonstrated that these genes exhibit excellent diagnostic performance in liver tissue, achieving 100% sensitivity and specificity. Collectively, these findings highlight glycosylation-related gene signatures as robust indicators of breast cancer-associated liver alterations and suggest that dysregulated hepatic glycosylation represents a biologically meaningful axis linking tumor progression with systemic metabolic and glycomic remodeling. This work provides a framework for exploring glycosylation-based biomarkers and therapeutic targets in cancer-associated organ dysfunction.

  • Effects of Epigallocatechin-3-Gallate in Preventing 5-Fluorouracil-induced Liver Injury in AML-12 Cell Line

    by Melek Akıncı, Çağatay Oltulu, Elvan Bakar, Zatiye Ayca Cevikelli Yakut

    This study aimed to assess the potential of epigallocatechin-3-gallate (EGCG) in mitigating 5-fluorouracil (5-FU)-induced hepatotoxicity using the AML12 cell line. In our study, we utilized the AML-12 cell line and divided it into four groups: control, 5-FU, EGCG, and EGCG+FU. The IC50 values were determined using the MTT assay. Expression levels of antioxidant system-associated genes, including Glutathione, catalase, and superoxide dismutase, were analyzed through qRT-PCR. Additionally, qRT-PCR analysis was employed to evaluate the expression of apoptosis-associated genes such as Caspase (Cas)-9, Apaf-1, Cas-3, Bax, and Bcl-2. Furthermore, the gene expressions of p53 and the smac/DIABLO were investigated. When EGCG was administered together with 5-FU GSH, SOD, and CAT mRNA expression levels increased. 5-FU administration statistically significantly elevated smac/DIABLO, Bax, Apaf-1, Bcl-2, and Cas-3 mRNA expression levels by stimulating apoptosis. When EGCG was administered together with 5-FU, Cas-9, Bax, Apaf-1, p53, Cas-3 and smac/DIABLO mRNA expressions elevated significantly, indicating the elimination of damaged structures through apoptosis. In conclusion, our findings indicate that EGCG confers hepatoprotective effects against 5-FU-induced damage through its antioxidant properties. Moreover, EGCG enhances the anticancer efficacy of 5-FU by promoting apoptosis, thereby facilitating the elimination of damaged cells. These results suggest a potential therapeutic synergy between EGCG and 5-FU in managing liver injury and cancer treatment.

  • Organ-specific effects of curcumin on favipiravir-induced oxidative stress: renal benefit and hepatic risk

    by Melek Akinci, Zatiye Ayca Cevikelli-Yakut, Elvan Bakar, Cagatay Oltulu

    Fa vipiravir (FAV), an antiviral for influenza and COVID-19, can provoke hepatotoxicity and nephrotoxicity. Curcumin (CUR) has antioxidant and anti-inflammatory properties that may protect against FAV-induced toxicity. Despite the widespread clinical use of FAV, to our knowledge, no in vivo animal study has yet examined its organ-specific oxidative injury profile in parallel with the putative dual, organ-directed actions of CUR. This study evaluated whether curcumin can mitigate favipiravir-induced oxidative and apoptotic damage in rat liver and kidney. Male Wistar rats received FAV (100 mg/kg i.p.) and CUR (100 or 200 mg/kg p.o.) for 14 days. Serum biochemistry analysis was performed to assess levels of ALT, AST, IL-6, MDA, TNF-α, and GSH. Additionally, histopathological examination and TUNEL assay were conducted on kidney and liver tissues. ALT, AST, and cytokines did not differ among groups. MDA remained unchanged in the FAV-alone group but rose significantly with CUR co-treatment, signifying CUR-driven amplification of oxidative stress, especially in hepatic tissue. Histopathological analysis revealed liver and kidney damage from FAV, with CUR exacerbating liver damage but offering partial protection to kidney structures. The TUNEL assay showed reduced apoptosis in the kidneys with CUR, especially at higher doses. FAV causes sub-clinical liver and kidney injury that is not accompanied by lipid peroxidation or enzyme leakage at 14 days. CUR exerts dual actions—mitigating renal apoptosis yet amplifying hepatic lipid peroxidation—highlighting an organ-specific risk–benefit ratio that should be weighed before empirical antioxidant supplementation during FAV therapy.

  • Open Access

    Brominated flame retardant BDE-99 promotes apoptosis by intrinsic mitochondrial pathway in rat liver

    by Ayşegül Çerkezkayabekir, Elvan Bakar, Deniz Yüksel Yence

    This study examined in vivo effects of 2,2’,4,4’,5-pentabromodiphenyl ether (BDE-99) on the liver of Wistar Albino rats (250-300 gr) in doses of 0.05 mg/kg and 0.1 mg/kg for ten days by gavage. Our objective was to investigate the effects of BDE-99 on the apoptotic process in the liver. Previous studies have shown that BDE-99 causes accumulation and oxidative damage in various tissues, especially the liver. Although the primary mechanism of BDE-99 toxicity is known to involve oxidative stress, limited information is available on its specific impact on apoptosis. Therefore, immunoreactivity of Proliferating Cell Nuclear Antigen (PCNA), Vimentin and Topoisomeraz2A (TOP2A) and Topoisomeraz2B (TOP2B) and Terminal deoxynucleotidyl transferase dUTP Nick End Labeling (TUNEL) were determined in the liver. Superoxide dismutase (SOD), Glutathione peroxidase (GPX) and Catalase (CAT) activities were measured in the liver. qRT-PCR analyses for the p53, Bax, Bcl-2, PCNA and Vimentin genes were carried out from paraffin-embedded liver tissues. Cell membrane damage, hypertrophy, endothelial injury, mononuclear cell infiltration in the liver were determined by Hematoxylin & Eosin. Immunoreactivity of TUNEL, Vimentin, TOP2A and TOP2B increased in both doses, but immunoreactivity of PCNA significantly increased only 0.1 mg/kg BDE-99 dose (p < 0.05). SOD and GPX activities increased but CAT activity decreased significantly (p < 0.05) in the liver. Bax, Bcl-2, PCNA, Vimentin gene expressions increased in a dose-dependent manner and p53 expression increased only in 0.1 mg/kg BDE-99. In conclusion, our results point out BDE-99 inducing apoptosis of the intrinsic mitochondrial pathway in rat liver and indicate that exposure to BDE-99 is possible to be a potential risk factor for liver diseases.


  • Cornus mas ameliorates AlCl 3 -induced Alzheimer’s disease in rats with metabolic syndrome by regulating inflammation and oxidative stress

    by Zatiye Ayça Çevikelli Yakut, Elvan Bakar, Filiz Sanal, Dicle Çevik, Çetin Hakan Karadağ, Etil Güzelmeriç

    Alzheimer's disease (AD) results from different risk variables, such as metabolic syndrome (MetS) and environmental factors. The benefits of Cornus mas L. on diabetes are well-known. However, the impacts of C. mas fruits on AD or MetS-related cognitive dysfunction have not yet been studied. We evaluated the impact of C. mas fruit (80% ethanol) extract in an animal model of MetS and AD. Male Spraque-Dawley rats were administered a high-fat, high-sugar diet for 105 days alone or with an AlCl3 intraperitoneal injection for the last 60 days. C. mas fruit extract (400, 700, and 1000 mg/kg peroral) was administered for 60 days. After conducting behavioral tests and measuring blood pressure, hippocampal tissues and serum samples were obtained. The phytochemical analyses were conducted on C. mas fruit extract. C. mas alleviated MetS by reducing blood glucose, total cholesterol, and systolic blood pressure levels. Behavioral tests demonstrated that C. mas improves AlCl3-related cognitive decline in rats with MetS, which was supported by the neuroprotective effect of C. mas in histological analysis. C. mas dose-dependently reduced amyloid-β, malondialdehyde levels, acetylcholinesterase activity in the hippocampus, proinflammatory cytokines in serum, and elevated glutathione levels in the hippocampus. Phytochemical analyses revealed that C. mas fruit contains loganic acid, cornuside, and anthocyanins. C. mas fruit extract in every three doses given could improve cognitive decline due to MetS and AlCl3 through alleviation of MetS, oxidative stress and inflammation, prevention of amyloid deposition, and increased cholinergic transmission.


  • Open Access

    Determination of the effects of irisin hormone in SKMEL-30 cells

    by Nebiye Pelin Turker, Elvan Bakar

    Melanocytes, the skin's pigment-producing cells, are the source of the skin cancer known as melanoma. Numerous variables, including as immune system interactions, tumor microenvironment, and genetic alterations, have an impact on the development and behavior of melanoma. The purpose of this study was to ascertain the impact of irisin on melanoma cells. The molecular effects of irisin SKMEL-30 on human melanoma cancer cells were examined for this aim. By using MTT technique, the effects of irisin on cell growth were examined. Real-time polymerase chain reaction was used to examine changes in gene expression level. The concentrations of sialic acid were measured using spectrophotometry. In the investigation, the irisin IC50 value for a 24-hour application was determined to be 30 nM. In comparison to the control group, sialic acid levels in the irisin-treated group of SKMEL-30 cells were significantly lower. In the qRT-PCR investigation, ST8SIA-2, one of the glycosyltransferase genes, increased 12.591-fold in the application group whereas cas8, one of the apoptotic genes, increased 82.481-fold. In conclusion, flow cytometry analyses proved that administration of 30 nM irisin to SKMEL-30 cells influences cell proliferation but does not cause apoptosis. It was shown that sialic acid substitution reduced the proliferative and metastatic potential of SKMEL- 30 cells.

  • Galanginin Protects AML-12 Cells Against Dactinomycin Induced Hepatotoxicity

    by Melek Akinci, Çağatay Oltulu, Elvan Bakar, Zatiye Ayça Çevi̇kelli̇ Yakut


  • Puerarin Protects from Methotrexate Induced Hepatotoxicity in AML-12 Cells

    by Melek Akinci, Çağatay Oltulu, Elvan Bakar, Zatiye Ayça Çevi̇kElli̇ Yakut


  • Topotekan, karvakrol, epigallokateşin gallat ve kombinasyonlarının nöroblastom ve astrosit hücrelerinde apoptotik süreç üzerine etkisinin değerlendirilmesi

    by Çağatay Oltulu, Melek Akinci, Elvan Bakar

    Neuroblastoma is the sympathetic nervous system cancer. It most commonly affects children under 5 years of age and is the most common solid tumor in childhood. Topotecan is a topoisomerase 1 inhibitor. Carvacrol and Epigallocatechin gallate are naturally derived substances with anticancer, antioxidant, and apoptotic properties. The aim of our study was to evaluate the effects of topotecan, carvacrol, EGCG, topotecan+carvacrol, and topotecan+ epigallocatechin gallate combinations on the apoptotic signaling pathway. IC50 values were determined in neuroblastoma and healthy astrocyte cells using the MTT assay. Apoptotic mRNA expressions (topoisomerase 1 and 2, p53, BCL2, BAX, caspase 9, caspase 3, IL1, TNFα) in astrocytes and neuroblastoma cells at the neuroblastoma IC50 dose were analyzed using quantitative real-time PCR. We found that topotecan and carvacrol did not exhibit selective cytotoxic effects between healthy astrocytes and neuroblastoma cells. However, we found that the combination of topotecan+ epigallocatechin gallate and topotecan+carvacrol with epigallocatechin gallate showed selective cytotoxic effects on the neuroblastoma cell line compared to astrocyte cells. The obtained mRNA results can be interpreted as the initiation of apoptosis in neuroblastoma cells in the topotecan, carvacrol, epigallocatechin gallate, and topotecan+epigallocatechin gallate groups. Further studies are needed to investigate this matter in more detail.